Phio Pharmaceuticals PHIO
NASDAQ PHIO
$0.99 -0.01 (-1.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Phio Pharmaceuticals (PHIO) Gains from Sales and Divestitures (2012 - 2026)

Updated

Phio Pharmaceuticals' Gains from Sales and Divestitures came in at $3,000 for Q1 2026.

Analysis

Phio Pharmaceuticals (PHIO) Gains from Sales and Divestitures (2012 - 2026) Analysis & Trends

For FY2024, Phio Pharmaceuticals' Gains from Sales and Divestitures was $6,000.

  • The Q1 2026 figure represents the highest quarterly Gains from Sales and Divestitures since Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Phio Pharmaceuticals 11.50 Mn 11.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 3,000.00
Dec 31, 2024 9,000.00
Mar 31, 2024 -3,000.00
Dec 31, 2012 -6,000.00
API Access

Phio Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PHIO&period=max&api_key=YOUR_API_KEY